webfact Posted March 20, 2022 Share Posted March 20, 2022 The Disease Control Department has asked critics not to undervalue the Favipiravir anti-viral medication, as it insists that the drug is efficacious in the treatment of COVID-19. Dr. Opart Karnkawinpong, the department’s director-general, cited a Thai study on the use of Favipiravir, jointly conducted by the Clinical Research Centre of the Faculty of Medicine at Siriraj hospital, the Bamrasnaradura Institute of Infectious Diseases, the Department of Disease Control and the Medical Sciences Department. Keep up to date with all things Thailand - Join our daily ASEAN NOW Thailand Newsletter - Click to subscribe He said today (Saturday) that the study was conducted on two groups of COVID-19 patients. The first 62 patients were administered 1,800 milligrams of Favipiravir twice day a day on the first day, followed by 800 milligrams twice a day for four days. The second group of 31 patients were not given Favipiravir. Discover Cigna’s range of health insurance solutions created for expats and local nationals living in Thailand - click to view Full story: https://www.thaipbsworld.com/thai-disease-control-dept-insists-favipiravir-is-effective-in-treating-covid-19/ -- © Copyright Thai PBS 2022-03-21 - Aetna offers a range of visa-compliant plans that meet the minimum requirement of medical treatment, including COVID-19, up to THB 3m. For more information on all expat health insurance plans click here. - Follow ASEAN NOW on LINE for breaking COVID-19 updates 2 Link to comment Share on other sites More sharing options...
ukrules Posted March 20, 2022 Share Posted March 20, 2022 For some reason two words spring to mind : Bomb detectors ???? 2 Link to comment Share on other sites More sharing options...
JoePai Posted March 21, 2022 Share Posted March 21, 2022 So they came to this conclusion after a study(?) of less that 100 patients ? 1 1 Link to comment Share on other sites More sharing options...
Popular Post mtls2005 Posted March 21, 2022 Popular Post Share Posted March 21, 2022 4 hours ago, ukrules said: For some reason two words spring to mind : Bomb detectors ???? Is rain-making one word or two? And how did the "amulet" group do? Better/worse than the untreated group? Suspect this is as much about fending off claims of corruption on the interwebs, rather than straight up malpractice. Most Favi patients have mild to moderate symptoms and would likely survive. From the OP-linked article A report, published in “Nature” as recently as last month and titled “The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials” concluded, however, that “Overall, Favipiravir possibly exerted no significant beneficial effect in the term of mortality in the general group of patients with mild to moderate COVID-19. We should consider that perhaps the use of antivirals once the patient has symptoms is too late and this would explain their low efficacy in the clinical setting. There upon, more clinical trials with a larger sample size are necessary to evaluate the exact efficacy and safety of this intervention.” 1 2 Link to comment Share on other sites More sharing options...
Popular Post ftpjtm Posted March 21, 2022 Popular Post Share Posted March 21, 2022 7 hours ago, webfact said: The first 62 patients were administered 1,800 milligrams of Favipiravir twice day a day on the first day, followed by 800 milligrams twice a day for four days. The second group of 31 patients were not given Favipiravir. Seems like a pretty small sample group. So they placed a 6 Billion baht order for a controversial drug based on a study of 93 patients? Must have been one helluva kickback involved... 4 Link to comment Share on other sites More sharing options...
MrJ2U Posted March 21, 2022 Share Posted March 21, 2022 Like there Sinovac and Sinopharm deals they've probably taken ages to work out kickbacks. They don't want to start that process again with a new and better drug. They've probably already spent the money. 2 Link to comment Share on other sites More sharing options...
Caldera Posted March 21, 2022 Share Posted March 21, 2022 11 hours ago, webfact said: He said today (Saturday) that the study was conducted on two groups of COVID-19 patients. The first 62 patients were administered 1,800 milligrams of Favipiravir twice day a day on the first day, followed by 800 milligrams twice a day for four days. The second group of 31 patients were not given Favipiravir. With tens of thousands new Covid cases daily (and that's just the official count!), you'd think they should have been able to conduct a somewhat more sizable study. 93 people, really? 1 Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now